STUDY QUESTION: Are pregnancy and birth rates affected by artificial oocyte activation (AOA) with SrCl 2 or calcimycin after ICSI for couples with male-factor infertility linked to abnormal sperm morphology or for couples with previous ICSI cycles of unexplained low fertilization or inadequate fertilization associated with impaired oocyte morphology?
Introduction
IVF and ICSI are effective treatments for infertility (Palermo et al., 1992; Steptoe and Edwards, 1992; Kissin et al., 2014) . Successful fertilization requires oocyte activation, which depends on a proper interaction between the gametes (Yeste et al., 2016) . Activation failure results in poor fertilization rates (Flaherty et al., 1998; Cheng et al., 2011; Clift and Schuh, 2013) .
Oocyte activation triggers a cascade of events including Ca 2+ oscillation, leading to fertilization and embryo development (Yeste et al., 2016) . In animal models, the duration, amplitude and frequency of Ca 2+ oscillation affect the normal oocyte activation and embryo development (Sfontouris et al., 2015) . The precise mechanisms underlying oocyte activation remain elusive. A likely mechanism is that the phospholipase C zeta (PLCζ) of a fertilizing spermatozoon produces inositol-1,4,5-trisphosphate within the oocyte which interacts with receptors in the endoplasmic reticulum, causing Ca 2+ oscillation (Ridgway et al., 1977; Steinhardt et al., 1977; Miyazaki et al., 1992 Miyazaki et al., , 1993 Wassarman et al., 2001; Ducibella et al., 2002; Saunders et al., 2002; Horner and Wolfner, 2008; Kashir et al., 2010; Amdani et al., 2013; Nomikos et al., 2013; Escoffier et al., 2014) . Reports suggest that abnormal sperm morphology reduces the rates of fertilization and implantation (De Vos et al., 2003; Lu et al., 2012; Greco et al., 2013) . The oocyte also contributes to the activation events via identified and unidentified factors (Tesarik et al., 2002; Eldar-Geva et al., 2003; Heindryckx et al., 2005 Heindryckx et al., , 2008 Combelles et al., 2010; Yelumalai et al., 2015) . Artificial oocyte activation (AOA) can repair a defective activation (Yeste et al., 2016) , improving ICSI outcomes (Montag et al., 2012) . Mechanical, electrical and chemical activation serve as AOA methods (Vanden Meerschaut et al., 2012; . Chemical AOA is the prominent, and it induces either a single, prolonged wave or pulsatile waves of intracytoplasmic Ca 2+ (Yeste et al., 2016; Murugesu et al., 2017) . Calcimycin, ionomycin, puromycin and 6-dimethylaminopurine increase membrane permeability to extracellular Ca
2+
, inducing a single, prolonged Ca 2+ wave (Rybouchkin et al., 1997; Ebner et al., 2015; Yeste et al., 2016) . Strontium chloride (SrCl 2 ), phorbol esters or anhydrous alcohol release the Ca 2+ from the endoplasmic reticulum in pulsatile waves (Kline and Kline, 1992; Kishikawa et al., 1999; Kim et al., 2014; Yeste et al., 2016) . AOA with calcimycin or SrCl 2 can improve outcomes for ICSI cycles of impaired fertilization (Yanagida et al., 2006; Chen et al., 2010; Kim et al., 2014; Murugesu et al., 2017) . Variable studies including retrospective designed analyses, historical comparisons or relatively underpowered studies have synthesized this evidence. Most of the studies have only examined calcimycin AOA, although SrCl 2 has shown potential for AOA (Kim et al., 2014; Yeste et al., 2016) . Recently, Lu et al. (2018) showed that SrCl 2 AOA cannot provoke calcium oscillation or parthenogenic division for human oocytes. However, Lu et al. used in vitro matured oocytes or oocytes characterized by smooth endoplasmic reticulum. In addition, there has been no comparative randomized clinical trial (RCT) to evaluate the relative effectiveness of calcimycin and SrCl 2 . Whether the sperm or the oocyte is most responsible for the activation defects remains unidentifiable from a clinical perspective (Murugesu et al., 2017) .
To address these questions, we compared SrCl 2 and calcimycin AOA with each other and with ICSI alone in this prospective RCT, identifying the rate of clinical pregnancy as a primary endpoint. To determine whether the sperm or the oocyte is most responsible, infertile couples included were those undergoing ICSI cycles for previous low fertilization (<30%) but normal semen parameters or first ICSI cycles for male-factor infertility with abnormal sperm morphology.
Materials and Methods

Trial design
The study adopted a randomized, open-label, three-arm, parallel-group, double-centre, superiority trial design (NCT02424214, registered at www. ClinicalTrials.gov). Two private IVF facilities in Egypt (Ibnsina IVF Centre, Suhag and Banoon IVF Centre, Asyut) conducted the trial. The trial included a screening period of 18 months (from the time of getting the consent to the start of assignment of participants). Research instructors disclosed the details to eligible couples. From January to April 2015, research instructors recalled participants for randomization and enrolment. The first couple was recruited on 30 April 2015, and the last oocyte retrieval was performed on 17 January 2016. Participants provided written informed consent. The ethics committees of the centres approved the study (Number 09; 02/2013) . Independent experts and safety committees oversaw this study.
Participants
Women were 18-40 years of age with a BMI of <31 kg/m 2 . Inclusion criteria were deliberately broad to include couples with two previous ICSI cycles of no or low fertilization (0-30%) or with male-factor infertility undergoing their first ICSI cycle. We classified previous cycles of low fertilization as 'unexplained low fertilization' or as 'low fertilization associated with impaired oocyte morphology', but within normal sperm limits. Impaired morphology of oocytes, according to the Istanbul Consensus, was nonconformity with the following definition: a spherical structure in a uniform zona pellucida with a uniform translucent cytoplasm free of inclusions and with a size-proper polar body (Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology, 2011). The male-factor infertility cycles (frozen-thawed sperm, surgically retrieved sperm or ejaculates containing <10 million spermatozoa/ml) undergoing their first ICSI attempt had 100% abnormal sperm morphology (including globozoospermia and tapered-head). Couples had primary infertility with no previous completed pregnancy or abortion. Exclusion criteria were couples with endometriosis, thin endometrial lining or pinhead sperm defects.
Randomization and masking
Using an online randomization tool (http://www.openepi.com/Random/ Random.htm), independent data managers assigned participants to SrCl 2 AOA, calcimycin AOA or ICSI alone with a 1:1:1 allocation ratio. Block randomization was performed to ensure equal representation of couples in the study groups. Each allocation was sealed in a sequentially numbered, opaque envelope. On 27 April 2015, independent instructors recorded each envelope number in each woman's case-record file. On Day 21 of the cycle preceding ICSI, research instructors opened the envelope and assigned the participant to the relevant group. Immediately, the instructors transferred the allocation result to the laboratory team, keeping gynaecologists and participants unaware of the result until the embryo transfer.
Stimulation protocol, embryo transfer and luteal-phase support Pituitary downregulation was attainable by subcutaneous GnRH-a (Decapeptyl 0.1 mg, Ferring, Saint-Prex, Switzerland) from Day 21 of the cycle preceding ICSI. On Day 2 of the ICSI cycle, women received 225-300 IU of rFSH (Gonal-F, Merck Serono) and hMG injections (Menogon, Ferring) with a 2:1 ratio, with the dose adjusted according to the response. When three follicles measured 18 mm diameter, final maturation was induced by 10 000 IU human chorionic gonadotropin (hCG, Choriomon, IBSA, Lugano, Switzerland) . Oocytes were collected 37 h later and the metaphase II (MII) were inseminated by ICSI (Palermo et al., 1992) . On Day 5, specified clinicians followed a standard protocol, transferring one to two blastocysts for each woman. For luteal phase support, women began intramuscular progesterone (100-mg, Prontogest, IBSA) from the day after oocyte retrieval to the 12th week of gestation, unless the biochemical pregnancy test was negative.
Sperm preparation, oocyte retrieval, denudation and ICSI Fresh, frozen-thawed and surgically retrieved sperm were prepared at room temperature by density-gradient centrifugation (PureSperm, Nidacon, Mölndal, Sweden) (Björndahl et al., 2010) . Samples were then washed and incubated in AllGrade Wash medium (LifeGlobal, Guilford, CT, USA). Follicles were aspirated into, and handled in, Global HEPES medium (LifeGlobal) at 37°C, using a tube warmer. With chemical and mechanical tools (80 IU hyaluronidase, LifeGlobal; Denudation Pipette, Vitrolife, Göteborg, Sweden), oocytes were denuded at 39 h after hCG. Immediately, ICSI was performed at 37°C, in Global HEPES (LifeGlobal).
Culture protocol and embryo scoring
In the two centres and across the study, laboratory variables were controlled using: only Minc-1000 incubators (Cook, USA); Global Total medium (LifeGlobal); 37 ± 0.1°C culture temperature verified by a thermocouple (Chino, Tokyo, Japan); 7.25 ± 0.02 pH validated weekly by a blood gas analyser (Epocal, Ottawa, Canada); group culture of three oocytes; 15 μl medium droplet in micro-droplet dish (Vitrolife) overlaid by 5 ml oil (NidOil, Nidacon); continuous culture from Day 0 through Day 5/6, without medium renewal; premixed gas (7.5% CO 2 , 5% O 2 and 87.5% N 2 ); and the same batches of disposables. Fertilization check and embryo grading were performed on Days 1, 3 and 5 of culture (Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology, 2011).
Interventions
Immediately after ICSI, AOA was performed and comprised incubation for 1 h in 10 mM SrCl 2 (Sigma, St Louis, MO, USA) diluted in Global Total medium or incubation for 20 min in a commercial calcimycin (Cult-active Ca-Ionophore; Gynemed, Lensahn, Germany). AOA droplets were 200 μl each in 60-mm dishes (353652, BD Falcon, USA) overlaid with 10 ml oil (NidOil) and were equilibrated overnight at 37°C and in an atmosphere of 7.5% CO 2 , 5% O 2 , and 87.5% N 2 (pH 7.25 ± 0.02).
Study outcomes
The primary endpoint was clinical pregnancy rate (positive heartbeat on ultrasonography at ≥4 weeks after ET). Secondary endpoints included the rates of (i) fertilization (fertilized oocytes with two pronuclei per MII oocyte injected); (ii) high-quality embryos on Day 3 (seven or eight blastomeres of equal-size and <10% fragmentation by volume); (iii) formed blastocyst on Day 5/6 from fertilized oocytes; (iv) high-quality blastocysts (blastocysts ≥3.1.1 grade, per fertilized oocyte); (v) biochemical pregnancy (positive b-hCG at ≥14 days following ET); (vi) ongoing pregnancy (pregnancy following week 12 of gestation); (vii) multiple pregnancy (≥two foetuses with a heartbeat); (viii) implantation (sacs with a heartbeat); (ix) miscarriage (pregnancy loss before gestational week 12); and (x) live birth (viable neonate at ≥30 weeks of gestation).
Statistical analysis
Previous cycles of low fertilization for women younger than 40 years of age showed a 16% clinical pregnancy rate (Murugesu et al., 2017) . This trial was powered to detect a 14% rise in pregnancy rate (16-30%) with 80% power at 5% significance level, requiring 342 participants (114 per arm) to undergo SrCl 2 AOA, calcimycin AOA or ICSI alone and reach the primary endpoint. An alternative was to enrol up to 450 women, to allow for any significant dropout. The independent data and safety committees performed an interim analysis at 343 participants, advising that no more enrolment is needed. Data were analysed using binomial logistic regression with log link, one-way ANOVA, Fisher's exact and Chi-square tests where appropriate. Between-clinician and between-embryologist differences were controlled by Fleiss' Kappa analysis (McHugh, 2012) . Results are reported as an intentionto-treat and per indication analyses and are presented as an absolute rate difference (ARD), odds ratio (OR) with 95% CI) or means with SD where appropriate. P < 0.05 was regarded as statistically significant. All analyses were performed using SPSS (version 22, IBM. Armonk, NY, USA).
Results
Between 27 April 2015 and 17 January 2016, we recruited 343 participants (SrCl 2 AOA = 115, calcimycin AOA = 113 and ICSI alone = 115) after excluding 49 (Fig. 1) . Patient and cycle characteristics were similar in the three groups (Table I) .
Overall (Table II) , the clinical pregnancy rate was significantly higher with SrCl 2 and calcimycin AOA than with ICSI alone (49, 42 and 27%; ARD 22, 95% CI: 9-33 and ARD 16, 95% CI: 3-27). SrCl 2 and calcimycin AOA also significantly increased the biochemical pregnancy rate compared with ICSI alone. The ongoing pregnancy rate was considerably higher with SrCl 2 and calcimycin AOA than with ICSI alone (42, 36 and 23%; ARD 19, 95% CI: 7-30 and ARD 14, 95% CI: 2-25). The implantation rate was significantly also higher with SrCl 2 and calcimycin AOA than with ICSI alone (32, 28 and 18%; ARD 14, 95% CI: 5-23 and ARD 10, 95% CI: 2-19). These results culminated in significantly higher rates of live birth for SrCl 2 and calcimycin AOA than for ICSI alone (40, 33 and 18%; ARD 22, 95% CI: 10-33 for SrCl 2 and ARD 14, 95% CI: 3-25). The rates of cancelled transfer, chemical pregnancy, miscarriage and multiple pregnancy were similar between the groups. Both SrCl 2 and calcimycin AOA resulted in similar rates of ongoing pregnancy, implantation and live birth (Supplementary Table SV 392 women were assessed for eligibility 360 women were eligible, of whom 17 decided to freeze all embryos before recruitment. Therefore, 343 were assigned to three groups and produced 3867 MII oocytes 32 women were excluded -18 declined to participate -4 had diabetes -6 had endometriosis -4 had poor endometrium 115 women were included in the analysis, of whom 108 reached Day 5 transfer.
-4 women had poor embryo development and did not reach transfer -1 woman developed OHSS and had her embryos frozen -2 women were lost to follow-up -9 women had poor embryo development and did not reach transfer -2 women developed OHSS and had their embryos frozen -1 woman was lost to follow-up 115 women were included in the analysis, of whom 103 reached Day 5 transfer.
113 women who produced 1310 MII oocytes were assigned to intervention group II (oocyte activation using calcimycin for 20 min post-ICSI).
-10 women had poor embryo development and did not reach transfer -1 woman developed OHSS and had her embryos frozen -3 women were lost to follow-up 113 women were included in the analysis, of whom 99 reached Day 5 transfer. and ongoing pregnancy, implantation, live birth and live-birth implantation, whereas SrCl 2 AOA and ICSI alone were comparable, as were SrCl 2 and calcimycin AOA were comparable (Supplementary  Tables SII and SV) . SrCl 2 AOA resulted in significantly greater rates of fertilization, topquality embryo and compaction on Day 3, blastocyst development, high-quality blastocysts and cryopreservation compared with ICSI alone (all P < 0.0001; Table III ). Calcimycin AOA also resulted in significantly higher rates of fertilization, blastocyst formation and cryopreservation compared with ICSI alone (P = 0.003, P = 0.026 and P < 0.0001; Table III ). The embryological outcomes for the subgroup analyses are shown in Supplementary Tables SIII and SIV.
Discussion
To our knowledge, this RCT is the first to compare SrCl 2 and calcimycin AOA after ICSI to ICSI alone for cycles of previous low fertilization or male-factor infertility. Overall, this trial demonstrated significantly higher rates of clinical pregnancy and live birth for either SrCl 2 or calcimycin AOA after ICSI compared with ICSI alone, whereas SrCl 2 and calcimycin AOA were comparable. Our findings concur with a recent meta-analysis (Murugesu et al., 2017) .
Among couples with previous ICSI cycles of low fertilization, SrCl 2 AOA was more effective than ICSI alone, whereas calcimycin AOA was comparable to ICSI alone. In this subgroup, neither sperm entry nor ICSI appears sufficient to initiate the oocyte activation. This is likely to relate the activation defects to the oocyte (Miyara et al., 2003; Ebner et al., 2006; Xing et al., 2011; Kilani and Chapman, 2014) . Reports suggest that ICSI with SrCl 2 AOA appears to stimulate pulsatile waves of Ca 2+ oscillation from the endoplasmic reticulum during fertilization and further development (Kline and Kline, 1992; Kishikawa et al., 1999; Kim et al., 2014; Yeste et al., 2016) . Although SrCl 2 AOA did not show signs of Ca 2+ oscillation or parthenogenetic division for in-vitro matured oocytes (Lu et al., 2018) , this situation may differ from the MII oocytes undergoing ICSI with AOA. Therefore, given its potential to improve ICSI outcomes, further studies are required to identify whether SrCl 2 AOA activates the oocyte by Ca 2+ oscillation or other mechanisms. For calcimycin AOA and previous ICSI cycles of low fertilization, our findings showed that calcimycin AOA and ICSI alone were comparable. Our results can be explained as calcimycin might be less effective than SrCl 2 because it induces a single Ca 2+ wave that is not converted into oscillation. Although our observations contradict a recent metaanalysis (Murugesu et al., 2017) yet concur with an earlier one (Sfontouris et al., 2015) , the conclusions from the meta-analyses seem to be not substantial due to the heterogenous designs of their studies. Therefore, calcimycin AOA appears to be not beneficial for ICSI cycles with previous impaired fertilization, but normal sperm parameters. Among couples with male-factor infertility, calcimycin AOA was superior to SrCl 2 AOA or ICSI alone. It is likely that when the problem results from male-factor infertility, Ca 2+ oscillation is functional in the oocyte, but it has insufficient stimulation by the ICSI alone with affected sperm (Vanden Meerschaut et al., 2013; Ferrer-Buitrago et al., 2018 Duration of infertility (years): mean ± SD 6 ± 2.7 6 ± 2.5 6 ± 2.2
Basal FSH (IU/L): mean ± SD 6 ± 1.2 6 ± 1.3 6 ± 2
Antral follicle count: mean ± SD 15.0 ± 2.2 14.0 ± 2.1 14.3 ± 2.3
Total FSH/hMG: mean ± SD 2245 ± 244 2294 ± 195 2264 ± 227 Impaired-fertilization cycles:
Previous fertilization failure: n (%) 7 (6) 5 (4) 7 (6) Previous low fertilization (<30%) with average oocyte quality: n (%) 14 (12) 13 (12) 12 (11) Previous low fertilization (<30%) associated with impaired oocyte quality: n (%) 26 (23) 27 (23) 24 (21) Male-factor infertility cycles:
Frozen-thawed sperm of affected-morphology samples: n (%) 22 (19) 24 (21) 23 (20) Surgically retrieved sperm of affected-morphology samples: n (%) 19 (17) 21 (19) 22 (19) Globozoospermia: n (%) 4 (3) 3 (3) 5 (4) 100% tapered-head sperm: n (%) 23 (20) 20 (18) 22 (19) Number of oocytes collected: mean ± SD 14 ± 9.4 13 ± 9.1 12 ± 8.0
Number of mature oocytes: mean ± SD 13 ± 6.5 12 ± 8.0 11 ± 6.2
Number of embryos transferred: mean ± SD 1.7 ± 0.5 1.6 ± 0.5 1.6 ± 0.5
Comparison of the differences between the three groups was performed by one-way ANOVA and the chi-square test where appropriate.
surrounding medium, boosting the initiation of Ca 2+ oscillation (Yeste et al., 2016) . In this situation, SrCl 2 may have less effect because the defect is not with the Ca 2+ oscillation machinery itself, just the initiation of oscillation. Our observations concur with a recent metaanalysis (Murugesu et al., 2017) as it also included cycles with affected sperm function. Therefore, calcimycin AOA appears promising for ICSI cycles with abnormal sperm morphology. Regarding embryo development, AOA with SrCl 2 or calcimycin gave significantly better results than conventional ICSI in the overall and subgroup analyses. The effect sizes for SrCl 2 were larger than for calcimycin. Both AOA protocols were superior to ICSI alone for the blastocyst cryopreservation rate, suggesting that, besides the clinical improvements observed, AOA might improve the cumulative pregnancy rate. The improvements in embryo development could have resulted from restoration of Ca 2+ oscillation to physiological or supraphysiological status. However, the mechanisms by which this restoration might have occurred are beyond this study, and whether possible supraphysiological Ca 2+ oscillation might have epigenetic effects remains a subject for further investigation. Previous studies (Murugesu et al., 2017) have shown that the clinical pregnancy rate is 16% for ICSI cycles with previous low fertilization. This rate appears relatively lower than that we observed in our facilities and we reported for this group. In our study, the rigorous control for the laboratory and clinical confounders, the relatively young age of women included (~32), and the short time of conduct seemed to be reflected in the observed outcomes in the three groups.
To limit the sample size required, the margin of superiority was set at 14%, which is a relatively high. This margin was considered because although calcimycin and SrCl 2 appear safe, this safety has not been proved unequivocally (Yeste et al., 2016) .
Our study has several strengths. It represents, to our knowledge, the first RCT with an appropriate sample size to compare SrCl 2 to calcimycin for AOA. Although clinical pregnancy was the primary outcome, ongoing pregnancy and live birth rates were also assessed. Our findings provide insight into the relative suitability of SrCl 2 and calcimycin for AOA for particular causes of infertility, which can improve the outcomes for subgroups of patients who experience poor outcomes of ICSI. Our study also has several limitations. The open-label trial design might have introduced bias, although randomization, at least partly, addressed this possibility. The study did not include a longitudinal follow-up period, so further evidence regarding the safety of AOA is still required. The study included couples with different indications for ICSI, rather than focusing on a single subgroup, but post hoc analyses were performed to determine the particular effects of AOA in these subgroups.
In conclusion, in our study population, ICSI followed by AOA with SrCl 2 or calcimycin was associated with significantly better embryological and clinical outcomes than ICSI alone. Calcimycin AOA appears effective in overcoming defects related to abnormal sperm morphology, whereas SrCl 2 AOA appears to improve outcomes for ICSI cycles characterized by previous impaired fertilization. In consideration of the current lack of knowledge regarding the long-term safety and transgenerational effects of AOA, we do not recommend this treatment for the general ICSI population. Instead, we recommend that more studies are performed, to further elucidate the mechanisms that underlie our findings, in particular those related to SrCl 2 AOA. We also recommend that a multicentre trial is conducted to identify the cumulative live birth rate and to assess the health of the offspring as primary outcomes. Until these studies have been conducted, we recommend that AOA should be used cautiously, and the advantages and disadvantages regarding its use should be weighed in each case.
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